95093-99-5
95093-99-5
Chemical Structure
(R)-Carvedilol
Synonym(s): (R)-BM 14190
- CAS No.: 95093-99-5
- Formula:C24H26N2O4
- Molecular Weight:406.47
IUPAC Name: (R)-1-((9H-carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol
InChIKey: OGHNVEJMJSYVRP-QGZVFWFLSA-N
SMILES: O[C@H](CNCCOC1=CC=CC=C1OC)COC2=CC=CC(N3)=C2C4=C3C=CC=C4
Biological Activity: (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca2+ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-Carvedilol | 98.78% | (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca2+ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-Carvedilol-d4 | (R)-Carvedilol-d4 is deuterium labeled (R)-Carvedilol (HY-B0006C). (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca2+ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VK-II-86 | 93.33% | VK-II-86 is a Carvedilol (HY-B0006) analogue lacking antagonist activity at β-adrenoceptors, in hypokalaemia. VK-II-86 prevents hypokalaemia-induced ventricular arrhythmia through multi-channel effects. VK-II-86 prevents all hypokalaemia-induced changes in ion channel activity and oxidative stress. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB209995 | SB209995 is an active compound. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-Hydroxy carvedilol | 3-Hydroxy carvedilol is an active compound. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carvedilol metabolite 4-Hydroxyphenyl Carvedilol | 98.42% | 4-Hydroxyphenyl Carvedilol, a metabolite of Carvedilol, is an active metabolite of Carvedilol (HY-B0006) and is produced via CYP2D6-mediated oxidation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carvedilol | 99.98% | Carvedilol (BM 14190) is a non-selective β/α-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-Carvedilol | 98.82% | (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carvedilol-d3 | 98.57% | Carvedilol-d3 is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carvedilol impurity 8 | Carvedilol impurity 8 is an impurity of Carvedilol. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carvedilol impurity 6 | Carvedilol impurity 6 (N-Isopropyl carvedilol) is an impurity of Carvedilol. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
O-Desmethylcarvedilol | 97.4% | O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol (HY-B0006). O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2R4496C) mutation (IC50 = 7.62 µM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol (HY-B0468) in conscious rabbits (ED50s = 32 and 5 µg/kg, respectively). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wu T, et al. Protective effects of S-carvedilol on doxorubicin-induced damages to human umbilical vein endothelial cells and rats. J Appl Toxicol. 2019 Aug;39(8):1233-1244. [Content Brief]
- [2]. Zhang J, et al. Non-β-blocking R-carvedilol enantiomer suppresses Ca2+ waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure. Biochem J. 2015 Sep 1;470(2):233-42. [Content Brief]
- [3]. Sardar PK, et al. Oral delivery of the non-β-blocking R-carvedilol enantiomer for skin cancer chemoprevention in SKH-1 mice. AAPS Open. 2025;11:1. [Content Brief]
